Phase
Startup
TRANSIENT PHARMA
Innovative systemic anti-inflammatory treatments.
Transient Pharma develops innovative systemic anti-inflammatory treatments, focusing initially on gastrointestinal inflammatory disorders and curbing the excessive inflammation during acute infections.
Transient Pharma´s groundbreaking research, originating from Professor Artur Schmidtchen’s lab at Lund University, has led to the development of TIM-03, a proprietary peptide with promising therapeutic potential. The peptide has demonstrated multifunctional properties consisting of strong anti-inflammatory effects and antimicrobial effects both in vitro and in vivo.
Did you know?
Our founder Professor Roland Andersson has been active within pancreatic cancer surgery for almost 40 years!
New technologies for next-gen antibody therapeutics
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
Introducing the fungal based industrial revolution
Automated microscopy image acquisition and analysis
Fighting iron deficiency
Implants of magnesium alloys
Developing future targeted immunotherapies in cancer
Digital service for patients
Ultrasound analysis for stroke risk assessment
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Effective treatments for brain tumors
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy
